Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Chemotherapy
100%
Overall Survival
82%
Progression Free Survival
65%
Abdominal Cancer
60%
Biliary Tract Cancer
47%
Adjuvant Therapy
45%
Malignant Neoplasm
45%
Hazard Ratio
44%
Cholangiocarcinoma
41%
Diseases
39%
Small Cell Lung Cancer
36%
Gemcitabine
36%
Cylindroma
36%
Arm
36%
Survival Rate
31%
Phase III Trials
29%
Platinum
29%
Cisplatin
28%
Adverse Event
28%
Axitinib
27%
First-Line Chemotherapy
27%
Biological Marker
26%
Etoposide
25%
Rituximab
25%
Chemoradiotherapy
25%
Durvalumab
24%
Supportive Care
24%
Capecitabine Plus Oxaliplatin
24%
Maintenance Therapy
24%
Tyrosine-Kinase Inhibitor
24%
Randomized Controlled Trial
24%
Docetaxel
24%
Metastatic Carcinoma
22%
Oxaliplatin
21%
Neoplasm
21%
Epidermal Growth Factor Receptor Kinase Inhibitor
19%
Phase II Trials
19%
Propensity Score Matching
18%
Treatment Outcome
17%
Epidermal Growth Factor Receptor
17%
Brain Metastasis
17%
Radiation Therapy
16%
Colorectal Carcinoma
15%
Pancreas Cancer
15%
Non Small Cell Lung Cancer
15%
Adenocarcinoma
15%
Gastrectomy
15%
Tumor
15%
Disease Exacerbation
14%
Gallbladder Cancer
14%
Pharmacology, Toxicology and Pharmaceutical Science
Durvalumab
73%
Small Cell Lung Cancer
73%
Chemotherapy Regimen
67%
Overall Survival
55%
Platinum
54%
Etoposide
51%
Gemcitabine
36%
Cisplatin
36%
Adverse Event
33%
Diseases
28%
Tremelimumab
28%
Progression Free Survival
28%
Neoplasm
27%
Abdominal Cancer
24%
Pancreas Cancer
24%
Epidermal Growth Factor Receptor
24%
Biliary Tract Cancer
24%
Docetaxel
24%
Survival Rate
19%
Phase II Trials
18%
Biological Marker
16%
Programmed Cell Death
16%
Epidermal Growth Factor Receptor Kinase Inhibitor
15%
Phase III Trials
15%
First-Line Chemotherapy
15%
Lung Cancer
15%
Monotherapy
14%
Protein Tyrosine Kinase Inhibitor
13%
Adenoid Cystic Carcinoma
12%
Randomized Controlled Trial
12%
Brain Metastasis
12%
Capecitabine Plus Oxaliplatin
12%
Adenocarcinoma
12%
Marginal Zone Lymphoma
12%
Second-Line Chemotherapy
12%
Methylprednisolone
12%
Dexamethasone
12%
Pancreas Adenocarcinoma
12%
Paclitaxel
12%
Vismodegib
12%
Rituximab
12%
Observational Study
12%
Cyclophosphamide
12%
Heavy Metal
12%
Liver Cell Carcinoma
12%
Immune Deficiency
12%
Prednisolone
12%
Cohort Study
12%
Vincristine
12%
Ethanol
12%
Nursing and Health Professions
Chemotherapy
51%
Vascular Guide Wire
36%
Small Cell Lung Cancer
36%
Etoposide
36%
Durvalumab
36%
Overall Survival
28%
Progression Free Survival
17%
Disease Exacerbation
16%
Platinum
13%
Tremelimumab
13%
Fluorodeoxyglucose F 18
12%
positron emission tomographic scan
12%
Alcohol
12%
Methylprednisolone
12%
Patient-Reported Outcome
12%
Brain Metastasis
12%
Gemcitabine
12%
Dexamethasone
12%
Oncologist
12%
Palliative Therapy
12%
Maintenance Therapy
12%
Pancreas Cancer
12%
Non Small Cell Lung Cancer
12%
Docetaxel
12%
Hazard Ratio
11%
Patient Referral
10%
Confidence Interval
9%
Quality of Life
9%
Pancreas Adenocarcinoma
8%
Survival Rate
7%
Maximum Standardized Uptake Value
6%
Receiver Operating Characteristic
6%